{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000151","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.047872+00:00","generated_at":"2026-05-16T12:45:08.048344+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BeOne Medicines promotes Lai Wang to President, Global Head of R&D effective Jan 1, 2026","bullets":["Dr. Lai Wang appointed President, Global Head of R&D, overseeing R&D, business development, and alliance management.","Promotion effective January 1, 2026; annual salary $750,000 with target bonus of 75% of base salary.","One-time RSU equity award of $10M vesting in equal annual installments over four years.","Dr. Wang had served as Global Head of R&D since April 2021 and joined the company in 2011.","No family relationships or material interests in transactions with directors or officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000151","json":"https://secwatch.observer/filing/0001651308-25-000151.json","markdown":"https://secwatch.observer/filing/0001651308-25-000151.md","text":"https://secwatch.observer/filing/0001651308-25-000151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/0001651308-25-000151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/bgne-20251217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:45:08.048344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}